Skip to content

D&A at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$2B+13.1%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$4.38M+14.4%
UroGen Pharma logo
UroGen PharmaURGN
$75K+4.2%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$688K+14.7%
CG Oncology logo
CG OncologyCGON
$841K+3,404%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$537K-20.4%

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total debt$17.0M-7.9%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Debt / equity0.2×0.0×
Current ratio7.1×-4.0×

Where this comes from

Reported directly by Aura Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s D&A?
Aura Biosciences, Inc. (AURA) reported D&A of $274K in Q1 2026.
How has Aura Biosciences, Inc.'s D&A changed year-over-year?
Aura Biosciences, Inc.'s D&A decreased by 5.8% year-over-year, from $291K to $274K.
What is the long-term trend for Aura Biosciences, Inc.'s D&A?
Over 4 years (2021 to 2025), Aura Biosciences, Inc.'s D&A has grown at a 9.3% compound annual growth rate (CAGR), from $815K to $1.16M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.